Microsoft's Alliance with Immuno-Sequencing Company Adaptive Biotechnologies Can Be Called

Multiple Choice

Microsoft's alliance with immuno-sequencing company Adaptive Biotechnologies can be called "strategic" because it serves all of the following strategic purposes except

A) builds, sustains, or enhances Microsoft's core competence in artificial intelligence.
B) blocks a competitive threat from Amazon to become a healthcare industry player.
C) accelerates drug development and bring new therapies to patients sooner than if each party had "gone it alone."
D) opens up important new healthcare market opportunities for both alliance members.
E) contracts out certain value chain activities by both parties to outside vendors.